-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Initiates Coverage On Evommune with Overweight Rating, Announces Price Target of $36

Benzinga·12/01/2025 13:07:21
Listen to the news
Morgan Stanley analyst Judah Frommer initiates coverage on Evommune (NYSE:EVMN) with a Overweight rating and announces Price Target of $36.